FDA In Brief > FDA In Brief: FDA warns about safety concerns related to investigational use of Venclexta (venetoclax) for multiple myeloma

FDA In Brief > FDA In Brief: FDA warns about safety concerns related to investigational use of Venclexta (venetoclax) for multiple myeloma

FDA warns about safety concerns related to investigational use of Venclexta (venetoclax) for multiple myeloma

Today, the FDA posted a safety statement to alert health care professionals and patients about the suspension of a clinical trial of bortezomib and low-dose dexamethasone with or without Venclexta in patients with relapsed and refractory multiple myeloma, due to an increased risk of death for patients receiving Venclexta when it was combined with bortezomib and dexamethasone as compared to the control group. The FDA has required that patients in this clinical trial be discontinued from further treatment, because interim results from the trial demonstrate an increased risk of ...